SI3368541T1 - Sestavki in postopki za zaviranje arginazne dejavnosti - Google Patents

Sestavki in postopki za zaviranje arginazne dejavnosti

Info

Publication number
SI3368541T1
SI3368541T1 SI201630892T SI201630892T SI3368541T1 SI 3368541 T1 SI3368541 T1 SI 3368541T1 SI 201630892 T SI201630892 T SI 201630892T SI 201630892 T SI201630892 T SI 201630892T SI 3368541 T1 SI3368541 T1 SI 3368541T1
Authority
SI
Slovenia
Prior art keywords
compositions
methods
arginase activity
inhibiting arginase
inhibiting
Prior art date
Application number
SI201630892T
Other languages
English (en)
Inventor
Eric B. Sjogren
Jim Li
Zandt Michael Van
Darren Whitehouse
Original Assignee
Calithera Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences, Inc. filed Critical Calithera Biosciences, Inc.
Publication of SI3368541T1 publication Critical patent/SI3368541T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
SI201630892T 2015-10-30 2016-10-28 Sestavki in postopki za zaviranje arginazne dejavnosti SI3368541T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15
EP16860883.4A EP3368541B1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity
PCT/US2016/059342 WO2017075363A1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity

Publications (1)

Publication Number Publication Date
SI3368541T1 true SI3368541T1 (sl) 2020-10-30

Family

ID=58631120

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630892T SI3368541T1 (sl) 2015-10-30 2016-10-28 Sestavki in postopki za zaviranje arginazne dejavnosti

Country Status (36)

Country Link
US (4) US10065974B2 (sl)
EP (3) EP3693375B1 (sl)
JP (3) JP6833844B2 (sl)
KR (2) KR20220118559A (sl)
CN (4) CN108271371B (sl)
AU (3) AU2016343656B2 (sl)
BR (3) BR122020022280B1 (sl)
CA (1) CA3003271A1 (sl)
CL (4) CL2018001134A1 (sl)
CO (1) CO2018004750A2 (sl)
CR (3) CR20210390A (sl)
CY (1) CY1123557T1 (sl)
DK (1) DK3368541T3 (sl)
EA (1) EA038276B1 (sl)
EC (1) ECSP18040250A (sl)
ES (2) ES2808988T3 (sl)
HK (1) HK1252560A1 (sl)
HR (1) HRP20201046T1 (sl)
HU (1) HUE054972T2 (sl)
IL (3) IL258731B (sl)
LT (1) LT3368541T (sl)
MA (2) MA50636A (sl)
MD (1) MD3368541T2 (sl)
MX (1) MX2018005294A (sl)
MY (1) MY201783A (sl)
NZ (1) NZ742742A (sl)
PH (1) PH12018500899A1 (sl)
PL (1) PL3368541T3 (sl)
PT (1) PT3368541T (sl)
RS (1) RS60695B1 (sl)
SG (4) SG10201911402YA (sl)
SI (1) SI3368541T1 (sl)
TW (3) TWI710565B (sl)
UA (1) UA125289C2 (sl)
WO (1) WO2017075363A1 (sl)
ZA (4) ZA201803556B (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603364A (en) 2010-04-22 2015-06-26 Mars Inc Inhibitors of arginase and their therapeutic applications
EP3719024A1 (en) 2010-10-26 2020-10-07 Mars, Incorporated Arginase inhibitors as therapeutics
CN108271371B (zh) 2015-10-30 2021-02-09 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2018089490A1 (en) * 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
CN110382508B (zh) * 2016-12-22 2022-08-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
EP3621954B1 (en) * 2017-05-12 2022-03-09 Calithera Biosciences, Inc. Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
CN111712302B (zh) 2018-02-17 2023-09-19 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
WO2019177873A1 (en) * 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP3774843B1 (en) 2018-03-29 2022-05-25 Molecure SA Dipeptide piperidine derivatives
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
EP3917936A4 (en) * 2019-02-06 2022-12-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. ALKYBORONIC ACIDS AS ARGINASE INHIBITORS
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme Llc ARGINASE INHIBITORS AND METHODS OF USE
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
MX2023000056A (es) 2020-07-02 2023-04-12 Incyte Corp Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US20220041630A1 (en) * 2020-07-17 2022-02-10 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺
US20230295124A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2024086273A1 (en) 2022-10-21 2024-04-25 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
CN1229110C (zh) 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6720188B2 (en) 2000-07-06 2004-04-13 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
BRPI0413381A (pt) 2003-08-07 2006-10-17 Allergan Inc composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
JP2011519868A (ja) * 2008-05-05 2011-07-14 シェーリング コーポレイション 癌を処置するための化学療法剤の連続投与
CA2749853C (en) * 2009-01-26 2018-08-21 Trustees Of The University Of Pennsylvania Arginase inhibitors and methods of use
NZ603364A (en) 2010-04-22 2015-06-26 Mars Inc Inhibitors of arginase and their therapeutic applications
EP3719024A1 (en) * 2010-10-26 2020-10-07 Mars, Incorporated Arginase inhibitors as therapeutics
CN104857005B (zh) * 2010-12-31 2019-04-26 阿斯利康公司 精氨酸酶抑制剂及其使用方法
BR112014009415B1 (pt) 2011-10-19 2021-11-23 Mars, Incorporated Composição farmacêutica, composto inbidor de arginase e seus usos
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2013158262A1 (en) 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
JP2015536950A (ja) * 2012-11-02 2015-12-24 ファーマサイクリックス，インク． Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
MX2016005283A (es) * 2013-10-25 2017-02-20 Pharmacyclics Llc Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia.
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
US20180078515A1 (en) * 2015-03-20 2018-03-22 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
EP3313410A4 (en) 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108271371B (zh) 2015-10-30 2021-02-09 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
CR20210389A (es) 2021-09-16
CY1123557T1 (el) 2022-03-24
KR20180084063A (ko) 2018-07-24
CL2018001134A1 (es) 2018-10-26
TWI710565B (zh) 2020-11-21
ZA201803556B (en) 2021-02-24
AU2016343656A1 (en) 2018-06-07
CN108271371A (zh) 2018-07-10
ECSP18040250A (es) 2018-10-31
EA038276B1 (ru) 2021-08-04
PT3368541T (pt) 2020-07-06
IL258731A (en) 2018-06-28
PH12018500899A1 (en) 2018-10-29
DK3368541T3 (da) 2020-06-29
HK1252560A1 (zh) 2019-05-31
MY201783A (en) 2024-03-18
ZA201907091B (en) 2021-05-26
MD3368541T2 (ro) 2020-09-30
US20200223872A1 (en) 2020-07-16
US20170121352A1 (en) 2017-05-04
TW202146028A (zh) 2021-12-16
US10851118B2 (en) 2020-12-01
SG11201802961PA (en) 2018-05-30
IL281503A (en) 2021-04-29
ZA201907093B (en) 2021-03-31
WO2017075363A1 (en) 2017-05-04
EP4011887A1 (en) 2022-06-15
RS60695B1 (sr) 2020-09-30
US20180346489A1 (en) 2018-12-06
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
SG10201911402YA (en) 2020-02-27
EP3693375B1 (en) 2022-02-16
TWI775556B (zh) 2022-08-21
IL288225A (en) 2022-01-01
AU2020286278A1 (en) 2021-01-14
ES2808988T3 (es) 2021-03-02
ES2910928T3 (es) 2022-05-17
HUE054972T2 (hu) 2021-10-28
US10065974B2 (en) 2018-09-04
UA125289C2 (uk) 2022-02-16
LT3368541T (lt) 2020-09-25
MA50636A (fr) 2021-04-14
TW202110858A (zh) 2021-03-16
CN113150016A (zh) 2021-07-23
CR20210390A (es) 2021-10-19
JP6833844B2 (ja) 2021-02-24
MA43131B1 (fr) 2020-07-29
CL2019000820A1 (es) 2019-08-09
US10844080B2 (en) 2020-11-24
AU2016343656B2 (en) 2020-09-17
KR20220118559A (ko) 2022-08-25
CL2019000821A1 (es) 2019-08-09
CN113150015A (zh) 2021-07-23
BR122020022280B1 (pt) 2022-05-03
CR20180282A (es) 2018-11-30
JP2022071010A (ja) 2022-05-13
MX2018005294A (es) 2018-09-21
CN113201002A (zh) 2021-08-03
TWI734630B (zh) 2021-07-21
EP3368541A1 (en) 2018-09-05
BR112018008746B1 (pt) 2021-11-16
CN108271371B (zh) 2021-02-09
HRP20201046T1 (hr) 2020-10-16
EP3368541A4 (en) 2019-07-17
SG10201911406TA (en) 2020-01-30
AU2020286278B2 (en) 2022-03-17
EP3368541B1 (en) 2020-05-27
ZA201907092B (en) 2021-04-28
BR122020022275B1 (pt) 2022-05-03
TW201726692A (zh) 2017-08-01
EP3693375A1 (en) 2020-08-12
BR112018008746A8 (pt) 2019-02-26
IL258731B (en) 2021-04-29
CL2019000819A1 (es) 2019-08-09
AU2022203703A1 (en) 2022-06-16
IL281503B (en) 2022-01-01
US20210061822A1 (en) 2021-03-04
CO2018004750A2 (es) 2018-10-31
JP2021075543A (ja) 2021-05-20
CA3003271A1 (en) 2017-05-04
EA201891057A1 (ru) 2018-12-28
BR112018008746A2 (pt) 2018-10-30
KR102434308B1 (ko) 2022-08-19
JP2018533582A (ja) 2018-11-15
JP7032583B2 (ja) 2022-03-08
PL3368541T3 (pl) 2020-11-02

Similar Documents

Publication Publication Date Title
IL288225A (en) Preparations and methods for preventing arginase activity
IL267532B (en) Preparations and methods for inhibiting arginase activity
ZA201800328B (en) Compositions and methods for inhibiting arginase activity
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
GB201513304D0 (en) Compositions and Methods
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
HK1252911A1 (zh) 用於抑制可溶生物分子的生物活性的組合物以及方法
HK1254550A1 (zh) 用於抑制β-內酰胺酶的組合物和方法
IL252191B (en) Compositions and methods for modulating at2r activity
GB201512996D0 (en) Compositions and methods
GB201514413D0 (en) Compositions and methods
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201518167D0 (en) Methods and compositions
GB201514415D0 (en) Compositions and methods